Spots Global Cancer Trial Database for NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Official Title: Phase I Study of NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Study ID: NCT05661201
Study Description
Brief Summary: The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for the combination of NEROFE and doxorubicin. Participants will receive weekly doses of NEROFE and doxorubicin.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Contact Details
Name: Benjamin Weinberg, MD
Affiliation: Georgetown University
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
